Literature DB >> 18197544

Patient education: an efficient adjuvant therapy for hyperphosphatemia in hemodialysis patients.

Chiao-Yin Sun1, Kuo-Chuan Chang, Sue-Hsien Chen, Chiz-Tzung Chang, Mai-Szu Wu.   

Abstract

BACKGROUND: Hemodialysis and phosphate (P) binder therapy are the major methods to reduce the phosphate level in dialysis patients. However, dietary P restriction is necessary for adequate control. The successful dietary control is based on patient compliance. Patient education is the best method to assure the knowledge and drive of dietary control, which are the key features for patient compliance. The aim of the study is to investigate quantitatively the effect of patient education on serum P levels in hyperphosphatemic hemodialysis patients.
METHODS: We conducted a prospective self-control study. Fifty hemodialysis patients with a pre-dialysis serum P level greater than 6.0 mg/dL were studied. Intensified patient education was given. Serum P, calcium (Ca), and intact parathyroid hormone (iPTH) were evaluated before and one month after patient education.
RESULTS: Thirty-six (72%) patients had improved pre-dialysis P level (pre-education: 7.50 +/- 1.33; post-education: 5.85 +/- 1.20 mg/dL, p < 0.001) and Ca x P product (pre-education: 68.17 +/- 12.70; post-education: 54.70 +/- 11.87 mg(2)/dL(2), p < 0.001). The effect lasted for at least three months. There is no significant change on calcium levels. The only predictor of a successful patient education is the iPTH level (improved: 348.8 +/- 277.6; non-improved: 668.0 +/- 674.1 ng/mL, p = 0.021).
CONCLUSIONS: Patient education could be helpful and efficient in hyperphosphatemic control in dialysis patients. The patient education should be given before the serum iPTH level getting high.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197544     DOI: 10.1080/08860220701742047

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  3 in total

1.  Nutritional education for management of osteodystrophy (NEMO) trial: Design and patient characteristics, Lebanon.

Authors:  Mirey Karavetian; Saade Abboud; Hafez Elzein; Sarah Haydar; Nanne de Vries
Journal:  Nutr Res Pract       Date:  2014-01-29       Impact factor: 1.926

2.  Mineral and bone disorder in hemodialysis patients in the Tibetan Plateau: a multicenter cross-sectional study.

Authors:  Zong-Hui Dang; Chen Tang; Guo-Liang Li; Ciren Luobu; Zhen-Hua Ma; Jing-Feng Qu; Lamu Suolang; Li-Jun Liu
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

3.  Randomised controlled trial of a smartphone application-based dietary self-management program on haemodialysis patients.

Authors:  Songyi Pack; Jia Lee
Journal:  J Clin Nurs       Date:  2021-01-28       Impact factor: 3.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.